Alpha Sense BI

AUGUST 30, 2023

AI has become more prevalent in every part of asset management, from opportunity identification to due diligence to invest men t decision-making to perfor man ce analysis to ongoing portfolio management and more. Intelligent Search : Algorithms and other AI technologies make every search smarter.

Management 98

Management Biotech Due Diligence Algorithm 98

Alpha Sense BI

MAY 5, 2023

M&A Trends by Industry Healthcare The COVID-19 pandemic ushered in a wave of unprecedented innovation, progress, and transformation to the healthcare industry in 2020. Many pharma companies with expiring patents are on the hunt to acquire biotech companies to address gaps in drug pipelines.

Biotech 97

Biotech Capital Banking Startups 97

Alpha Sense BI

APRIL 19, 2024

Over the past few years, the technology industry has experienced dramatic highs and lows. 2020 and 2021 were marked by increased innovation, accelerated growth, and workforce expansion. trillion market evaluation by 2032 due to the ever-increasing number of companies integrating this technology.

Technology 69

Technology Technology Retail Biotech 69

Alpha Sense BI

APRIL 29, 2024

Traditional due diligence for start-up investors has historically been riddled with inefficiencies—tying up resources to sort through countless documents and copious amounts of data, and manually crafting market comparisons and performance. There is no doubt that generative AI has emerged as a powerful tool in the investment space.

Capital 52

Capital Due Diligence Biotech Startups 52

Engage3

MAY 19, 2022

Ken Ouimet, PhD Founder/Chairman, Technology Committee Ken Ouimet is the Chair of Strategic Planning and Founder of Engage3 and is credited with creating the retail revenue management and price optimization market. Fortune magazine listed Khimetrics as one of the 25 break-out innovative companies.

Retail 52

Retail Capital Finance Biotech 52

Alpha Sense BI

MARCH 13, 2024

According to an outlook published by PwC , “large-cap pharma companies are expected to continue pursuing mid-sized biotech companies to fill pipeline gaps in the face of impending patent cliffs. In January, HATCo announced its intent to acquire Summa Health of Ohio , a non-profit healthcare system, with a focus to “put innovation in.”

Pharmaceutical 59

Pharmaceutical Hospitals Due Diligence Biotech 59